ASX Announcements

19 Nov 2024	Results of Meeting

19 Nov 2024	Noxopharm 2024 AGM Corporate Presentation

19 Nov 2024	Noxopharm 2024 AGM Chair Address

12 Nov 2024	Noxopharm enhances 2024 cash position via R&D rebate

6 Nov 2024	Notification of cessation of securities - NOX

5 Nov 2024	Proposed issue of securities - NOX

5 Nov 2024	Additional convertible note for long-term shareholder

29 Oct 2024	September 2024 Quarterly Activities report and Appendix 4C

25 Oct 2024	2024 AGM Addendum to the Notice of Meeting and Proxy

14 Oct 2024	Minor correction to funding announcement

14 Oct 2024	AGM Letter of Access, Notice of Meeting and Proxy

11 Oct 2024	Unlisted Options Upcoming Expiry

10 Oct 2024	SOF-SKN manufacturer signed for HERACLES clinical trial

30 Sep 2024	Annual Report to shareholders

27 Sep 2024	Audited Financial Statements

27 Sep 2024	Appendix 4G and Corporate Governance Statement

27 Sep 2024	Proposed issue of securities - NOX

27 Sep 2024	New funding from sophisticated investors

17 Sep 2024	Noxopharm completes SOF-SKN formulation as clinical trial approaches

6 Sep 2024	Advanced funding secured ahead of R&D rebate

3 Sep 2024	Significant results from new brain cancer drugs

30 Aug 2024	Ceasing to be a substantial holder - Goodridge

29 Aug 2024	Appendix 4E Preliminary Final Report

19 Aug 2024	Noxopharm Targets Clinical Trial for First-in-Class Drug

14 Aug 2024	Significant CRO-67 Results in Pancreatic Cancer Studies

23 Jul 2024	June 2024 Quarterly Activities Report and Appendix 4C

28 May 2024	Noxopharm joins global Alliance for mRNA Medicines

14 May 2024	Milestone reached as SOF-SKN progresses to next level

29 Apr 2024	March 2024 Quarterly Activities Report and Appendix 4C

4 Apr 2024	Tour de Cure Grant for Brain Cancer Research

27 Feb 2024	Appendix 4D and Half Year 2024 Financial Report

13 Feb 2024	Noxopharm extends Hudson Institute strategic partnership

22 Jan 2024	December 2023 Quarterly Activities Report and Appendix 4C

18 Dec 2023	Change of Director's Interest Notice - GM

18 Dec 2023	Notification of cessation of securities - NOX

16 Nov 2023	Results of Meeting

16 Nov 2023	Noxopharm Enhances Cash Position via R&D Rebate

16 Nov 2023	Noxopharm 2023 AGM Corporate Presentation

16 Nov 2023	Noxopharm 2023 AGM Chair Address

27 Oct 2023	Unlisted Options Expiring on 16 December 2023

18 Oct 2023	mRNA Vaccine Enhancer Shows Inflammation Reduction

13 Oct 2023	September 2023 Activities Report and Appendix 4C

9 Oct 2023	Response to ASX Query

4 Oct 2023	US FDA grants Orphan Drug Designation for CRO-67

3 Oct 2023	Trading Halt

3 Oct 2023	Pause in Trading

28 Sep 2023	Latest CRO-67 data shows success in reducing cancer growth

28 Sep 2023	2023 AGM Notice of Meeting and Proxy

28 Sep 2023	2023 AGM Letter to Shareholders and Proxy

27 Sep 2023	Annual Report to shareholders

21 Sep 2023	Change of Director's Interest Notice - FB

18 Sep 2023	Change of Director's Interest Notice - FB

31 Aug 2023	Appendix 4E and Audited Financial Statements

31 Aug 2023	Appendix 4G and Corporate Governance Statement

24 Jul 2023	Notification of cessation of securities - NOX

14 Jul 2023	June 2023 Activities Report and Appendix 4C

5 Jul 2023	Upcoming Expiry of Listed Options (ASX Code NOXOA)

5 Jul 2023	Unlisted Options expiring on 23 July 2023

5 Jul 2023	Notification of cessation of securities - NOX

3 Jul 2023	Change of Director's Interest Notice - FB

29 Jun 2023	Change of Director's Interest Notice - FB

19 Jun 2023	Change of Director's Interest Notice - FB

19 Jun 2023	Change of Director's Interest Notice - BP

19 Jun 2023	Change of Director's Interest Notice - PM

19 Jun 2023	Details of Company Address

26 May 2023	IONIC Trial Abstract Published at ASCO

19 May 2023	Study results show new Sofra drug reduces inflammation

18 May 2023	Innovative Sofra research presented at European event

10 May 2023	Change of Director's Interest Notice - FB

8 May 2023	Upcoming Expiry of Listed Options (ASX Code NOXO)

4 May 2023	Change of Director's Interest Notice - FB

24 Apr 2023	March 2023 Quarterly Activities Report and Appendix 4C

6 Apr 2023	Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs

28 Mar 2023	Noxopharm Announces Novel mRNA Vaccine Enhancer

24 Feb 2023	Appendix 4D and Half Year 2023 Financial Report

22 Feb 2023	Noxopharm to Present Sofra Study at LUPUS 2023 Conference

27 Jan 2023	December 2022 Quarterly Activities Report and Appendix 4C

17 Jan 2023	DARRT-2 Trial Efficacy Phase to Commence

16 Dec 2022	NOX Pipeline Boosted by $1.5M Grant to Hudson Institute

15 Dec 2022	Change of Director's Interest Notice - FB

15 Dec 2022	Notification of cessation of securities - NOX

6 Dec 2022	Federal Innovation Connections Grant Awarded

2 Dec 2022	IONIC Trial Progresses as Veyonda Passes Safety Milestone

21 Nov 2022	Notification of cessation of securities - NOX

17 Nov 2022	Constitution

17 Nov 2022	Results of Meeting

17 Nov 2022	Noxopharm 2022 AGM Corporate Presentation

17 Nov 2022	Noxopharm AGM 2022 Chair's Address

16 Nov 2022	CEP-2 Safety Milestone Shows Veyonda Progress

10 Nov 2022	Noxopharm Enhances Cash Position via R&D Rebate

25 Oct 2022	Change in substantial holding

21 Oct 2022	September 2022 Quarterly Activities Report and Appendix 4C

18 Oct 2022	2022 AGM Notice of Meeting and Proxy

18 Oct 2022	2022 AGM Letter to Shareholders and Proxy

7 Oct 2022	Unlisted Options Expiring on 21 November 2022

26 Sep 2022	Noxopharm 2022 Annual Report

20 Sep 2022	Final Director's Interest Notice - GK

19 Sep 2022	Resignation of Dr Graham Kelly as Non-Executive Director

14 Sep 2022	Novel Dual-cell Therapy Results in Pancreatic Cancer

2 Sep 2022	Response to ASX Price Query (Correction to ASX Ticker)

2 Sep 2022	Response to ASX Price Query

25 Aug 2022	Appendix 4E and Audited Financial Statements

25 Aug 2022	Appendix 4G and Corporate Governance Statement

16 Aug 2022	Noxopharm & UNSW Pancreatic Cancer Research at US Conference

9 Aug 2022	CEP-2 Trial Passes Safety Milestone

2 Aug 2022	DARRT-2 Trial Safety Milestone and European Site Activated

27 Jul 2022	June 2022 Quarterly Activities Report and Appendix 4C

5 Jul 2022	Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial

22 Jun 2022	$1.45M Grant to Hudson Institute for Noxopharm Collaboration

14 Jun 2022	Hudson Institute Collaboration Secures mRNA Victoria Acceleration Fund Grant

7 Jun 2022	Noxopharm Corporate Presentation

27 May 2022	Veyonda Abstract Published at ASCO Annual Meeting 2022

28 Apr 2022	March 2022 Quarterly Activities Report and Appendix 4C

22 Mar 2022	Orphan Drug Designation Granted to Noxopharm by US FDA

28 Feb 2022	First Patient Treated in CEP-2 Sarcoma Trial

21 Feb 2022	Appendix 4D and Half Year 2022 Financial Report

1 Feb 2022	Initial Director's Interest Notice - GM

27 Jan 2022	December 2021 Quarterly Activities Report and Appendix 4C

10 Jan 2022	Noxopharm Presents at H.C. Wainwright BioConnect Conference

7 Jan 2022	Noxopharm Receives A$5.865M R & D Tax Rebate

5 Jan 2022	Noxopharm Announces Leadership Transition

14 Dec 2021	Noxopharm DARRT-2 Cancer Trial Update

2 Dec 2021	Notification of cessation of securities - NOX

2 Dec 2021	Change of Director's Interest Notice - GK

17 Nov 2021	Noxopharm Annual General Meeting Results

17 Nov 2021	Licencing Deal Expands Noxopharm Drug Opportunities

17 Nov 2021	Noxopharm 2021 AGM Corporate Presentation

17 Nov 2021	Noxopharm 2021 AGM Chairmans Address

16 Nov 2021	Retraction of Grant Announcement

15 Nov 2021	Trading Halt

15 Nov 2021	Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial

4 Nov 2021	DARRT-2 Trial Commences in the U.S.

29 Oct 2021	Unlisted Options Expiring on 30 November 2021

26 Oct 2021	Veyonda and Opdivo IONIC Study First Patient Dosed

25 Oct 2021	Patent Granted for Veyonda and Low Dose Chemotherapy

20 Oct 2021	Jobkeeper s323DB Notice

15 Oct 2021	2021 AGM Notice of Meeting and Proxy

15 Oct 2021	2021 AGM Letter to Shareholders and Proxy

14 Oct 2021	September 2021 Quarterly Activities Report and Appendix 4C

29 Sep 2021	Cleansing Notice

29 Sep 2021	Application for quotation of securities - NOX

27 Sep 2021	Veyonda Achieves Important U.S. Patent Claims

10 Sep 2021	Noxopharm 2021 Annual Report

9 Sep 2021	Noxopharm Updated Corporate Presentation

30 Aug 2021	Change of Registered Office and Principal Place of Business

26 Aug 2021	Appendix 4E and Audited Financial Statements

26 Aug 2021	Appendix 4G and Corporate Governance Statement

23 Aug 2021	Cleansing Notice

23 Aug 2021	Application for quotation of securities - NOX

23 Aug 2021	Pre-clinical Data Supports a Role for Veyonda in COVID-19

23 Aug 2021	NOXCOVID Program to Expand After Positive Phase 1 Results

19 Aug 2021	Trading Halt

13 Aug 2021	Cleansing Notice

13 Aug 2021	Application for quotation of securities - NOX

11 Aug 2021	Additional Information on US NCI Collaboration

9 Aug 2021	NOX and US Govt Peak Cancer Agency Announce Collaboration

5 Aug 2021	Veyonda Survival Advantage in LuPSMA Therapy Confirmed

27 Jul 2021	June 2021 Quarterly Activities Report and Appendix 4C

1 Jul 2021	DARRT-2 Study Receives IND Approval from FDA

29 Jun 2021	Noxopharm Secures Key European Patent Allowance for Veyonda

28 Jun 2021	Noxopharm Corporate Presentation

21 Jun 2021	Cleansing Notice

21 Jun 2021	Application for quotation of securities - NOX

10 Jun 2021	DARRT-2 Study Update and Clarification

8 Jun 2021	The Noxopharm Newsletter June 2021

4 Jun 2021	Noxopharm Set to Benefit From Novartis ASCO Data

31 May 2021	Becoming a substantial holder

31 May 2021	Change of Director's Interest Notice - FB

31 May 2021	Change of Director's Interest Notice - BP

31 May 2021	Cleansing Notice

31 May 2021	Appendix 2A

31 May 2021	Appendix 3G

31 May 2021	Noxopharm Extraordinary General Meeting Results

31 May 2021	New Independent Trial Data Supports Potential of Veyonda

13 May 2021	Noxopharm to Present to Share Cafe Hidden Gems Webinar

12 May 2021	NOXCOVID Trial Achieves Full Enrolment

7 May 2021	Cleansing Notice

7 May 2021	Appendix 2A

7 May 2021	Veyonda FDA Approved Trial to Commence

4 May 2021	Securities Trading Policy

30 Apr 2021	Cleansing Notice

30 Apr 2021	Appendix 2A

30 Apr 2021	Change of Director's Interest Notice - BP

30 Apr 2021	Lapsing of Unlisted Options

30 Apr 2021	Publications Positive Review of Veyonda in Chemotherapy

29 Apr 2021	Notice of General Meeting/Proxy Form

27 Apr 2021	March Quarterly Activities Report and Appendix 4C

22 Apr 2021	Veyonda Showing Potential to Prevent Cytokine Storm

22 Apr 2021	Pause in Trading

12 Apr 2021	Cleansing Notice

12 Apr 2021	Appendix 2A

6 Apr 2021	Veyonda Patent Lodged for Major Septic Shock Opportunity

29 Mar 2021	Corporate Presentation for Switzer Virtual Investor Day

19 Mar 2021	Noxopharm IONIC Immuno-Oncology Trial Commences

16 Mar 2021	ASX Small-Mid Cap Conference Corporate Presentation

8 Mar 2021	NOXCOVID Trial Advances to Final Stage

5 Mar 2021	Noxopharm Presents to H.C. Wainwright Global Conference

4 Mar 2021	Cleansing Notice

4 Mar 2021	Appendix 2A

2 Mar 2021	Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate

1 Mar 2021	Proposed issue of Securities - NOX

1 Mar 2021	Lapsing of Unlisted Options and Shortfall Shares

1 Mar 2021	Change of Director's Interest Notice - PM

26 Feb 2021	Change in substantial holding

26 Feb 2021	Change of Director's Interest Notice - GK

26 Feb 2021	Cleansing Notice

26 Feb 2021	Appendix 2A

24 Feb 2021	Company Announcement Regarding Appendix 3Y Disclosures

24 Feb 2021	Change in substantial holding

24 Feb 2021	Change of Director's Interest Notice - GK

23 Feb 2021	Noxopharm Updated Corporate Presentation February-March 2021

19 Feb 2021	Option Underwriting Agreement to Secure Funds

19 Feb 2021	Cleansing Notice

19 Feb 2021	Appendix 2A

16 Feb 2021	Noxopharm CEO Letter to Shareholders February 2021

16 Feb 2021	Appendix 4D and Half Year Financial Report

15 Feb 2021	Cleansing Notice

15 Feb 2021	Appendix 2A

15 Feb 2021	LuPIN Survival Outcome Confirmed by Conference Presentation

9 Feb 2021	Major Survival Benefit in Prostate Cancer Patients Announced

5 Feb 2021	Cleansing Notice

5 Feb 2021	Appendix 2A

3 Feb 2021	Cleansing Notice

3 Feb 2021	Appendix 2A

28 Jan 2021	Noxopharm To Present to ShareCafe Hidden Gems Webinar

25 Jan 2021	Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C

22 Jan 2021	Cleansing Notice

22 Jan 2021	Appendix 2A

13 Jan 2021	NOXCOVID Study Advances

12 Jan 2021	Unlisted Options Expiring 28 February 2021

6 Jan 2021	Noxopharm Shareholder Update 2021

23 Dec 2020	Federal Government Approved Future Overseas R&D Expenditure

15 Dec 2020	Cleansing Notice

15 Dec 2020	Appendix 2A

15 Dec 2020	Change of Director's Interest Notice - BP

15 Dec 2020	Change of Director's Interest Notice - FB

15 Dec 2020	Appendix 3G

11 Dec 2020	December Investor Webinar Recording

10 Dec 2020	Change in substantial holding

10 Dec 2020	Cleansing Notice

10 Dec 2020	Appendix 2A

8 Dec 2020	Noxopharm Corporate Presentation December Investor Webinar

7 Dec 2020	Pre-Clinical Breakthrough Discovery Set to Expand Pipeline

4 Dec 2020	Noxopharm December Investor Webinar Details

3 Dec 2020	Cleansing Statement

3 Dec 2020	Proposed issue of Securities - NOX

3 Dec 2020	Noxopharm Completes A$23m Placement to Fund Clinical Studies

1 Dec 2020	Appendix 2A

1 Dec 2020	Trading Halt

27 Nov 2020	Change of Director's Interest Notice - PM

27 Nov 2020	Lapsing of Unlisted Options

18 Nov 2020	Change of Director's Interest Notice - GK

18 Nov 2020	Cleansing Notice

18 Nov 2020	Appendix 2A

18 Nov 2020	Appendix 3G

18 Nov 2020	Further Independent Support for Veyonda as a Major I-O Drug

17 Nov 2020	Noxopharm Annual General Meeting Results

17 Nov 2020	Noxopharm 2020 AGM Corporate Update

17 Nov 2020	2020 AGM Chairman's Address

13 Nov 2020	Independent Discovery Validates DARRT Cancer Therapy

9 Nov 2020	Veyonda To Be Tested In Combination With Opdivo In Trial

5 Nov 2020	Dedicated Septic Shock Company Established

5 Nov 2020	NOXCOVID Study Cleared To Expand

3 Nov 2020	2020 Annual General Meeting Reminder

26 Oct 2020	Cleansing Notice

26 Oct 2020	Appendix 2A

26 Oct 2020	First Two Cohorts Enrolled in NOXCOVID Study

15 Oct 2020	Noxopharm September 2020 Quarterly Activities Report & Appendix 4C

14 Oct 2020	Cover Letter and Proxy Form - Annual General Meeting

14 Oct 2020	Notice of Annual General Meeting and Proxy Form

12 Oct 2020	LuPIN Study Achieves Final Patient Treatment

9 Oct 2020	Noxopharm CMO Discusses the NOXCOVID trial

9 Oct 2020	Unlisted Options Expiring 27 November 2020

9 Oct 2020	Cleansing Notice

9 Oct 2020	Appendix 2A

6 Oct 2020	Noxopharm Loan Terms Amended to Benefit Company

2 Oct 2020	First COVID-19 Patient Treated in Veyonda Study

21 Sep 2020	Noxopharm Corporate Presentation September 2020

18 Sep 2020	Noxopharm Appoints US Corporate Advisory and Consulting Firm

17 Sep 2020	Notification of Date of 2020 Annual General Meeting

15 Sep 2020	Annual Report to shareholders

15 Sep 2020	Appendix 4G and Corporate Governance Statement

9 Sep 2020	Noxopharm Appoints New Chair

8 Sep 2020	Global CRO To Execute DARRT-2 Prostate Cancer Study

1 Sep 2020	Veyonda COVID-19 Study Approved For Immediate Start

31 Aug 2020	Final Director's Interest Notice - ID

31 Aug 2020	Appendix 4E and Audited Financial Statements FY2020

31 Aug 2020	Appendix 4G and Corporate Governance Statement

31 Aug 2020	Noxopharm Announces Board Changes

14 Aug 2020	Appendix 2A - Shares

14 Aug 2020	Cleansing Notice

14 Aug 2020	Appendix 2A - Underwriter Options

14 Aug 2020	Results of Meeting

14 Aug 2020	Noxopharm August 2020 EGM Corporate Presentation

11 Aug 2020	Peer-Reviewed Publication Strengthens Case For Veyonda

6 Aug 2020	Noxopharm Extraordinary General Meeting Reminder

29 Jul 2020	Noxopharm June 2020 Quarterly Activities Report & Appendix 4C

24 Jul 2020	Change of Director's Interest Notice - FB

24 Jul 2020	Notice of Contravention of Listing Rule 10.11

23 Jul 2020	Noxopharm Discusses Converting Cold to Hot Cancer Tumours

22 Jul 2020	Receipt of cash payment for collateral shares

20 Jul 2020	Data Shows Idronoxil Holds Key to Problem of COLD Cancers

14 Jul 2020	Noxopharm July 2020 Newsletter Released

14 Jul 2020	Letter to Shareholders - Extraordinary General Meeting

14 Jul 2020	Notice of Extraordinary General Meeting/Proxy Form

8 Jul 2020	Corporate Presentation for the Reach Markets Virtual Event

3 Jul 2020	Ceasing to be a substantial holder

29 Jun 2020	Change of Director's Interest Notice - FB

22 Jun 2020	Change in substantial holding - amended

22 Jun 2020	Change in substantial holding

22 Jun 2020	Noxopharm Chair Letter to Shareholders

19 Jun 2020	COVID-19 Trial Program to Commence in Europe

18 Jun 2020	Change in substantial holding

18 Jun 2020	Change in substantial holding

18 Jun 2020	Change of Director's Interest Notice - BP

18 Jun 2020	Change of Director's Interest Notice - FB

18 Jun 2020	Change of Director's Interest Notice - PM

18 Jun 2020	Change of Director's Interest Notice - GK

18 Jun 2020	Appendix 2A - shares

18 Jun 2020	Appendix 2A - options

15 Jun 2020	Pro-rata Non-Renounceable Rights Issue Fully Allocated

9 Jun 2020	Rights Issue Close Date

5 Jun 2020	Webcast Overview of ASCO 2020 Annual Meeting NOX Posters

4 Jun 2020	Change of Director's Interest Notice - PM

4 Jun 2020	Change of Director's Interest Notice - ID

1 Jun 2020	Appendix 3G Adjustment to Option Exercise Prices

1 Jun 2020	ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer

28 May 2020	Listing Rule 6.22.2 Adjustment to Option Exercise Prices

22 May 2020	Proposed issue of Securities - NOX

21 May 2020	Despatch of Pro Rata Entitlement Offer Documents

19 May 2020	FDA allows Veyonda Pre-IND Submission for COVID-19

14 May 2020	Noxopharm ASCO Abstracts Live

13 May 2020	Appendix 2A

13 May 2020	Entitlement Offer Prospectus

13 May 2020	Entitlement Offer - Letter to Optionholders

13 May 2020	Entitlement Offer - Letter to Ineligible Shareholders

13 May 2020	Entitlement Offer - Letter to Eligible Shareholders

13 May 2020	Proposed issue of Securities - NOX

13 May 2020	$7.9 Million Fully Underwritten Entitlement Offer Announced

8 May 2020	Initial Director's Interest Notice - FB

8 May 2020	Appointment of New Board Member

7 May 2020	Trading Halt

1 May 2020	Change in substantial holding

1 May 2020	Change in substantial holding

30 Apr 2020	Noxopharm March 2020 Quarterly Report & Appendix 4C

30 Apr 2020	Abscopal Responses Achieved in Prostate Cancer

23 Apr 2020	Pipeline Expands With Potential New Brain Cancer Treatment

21 Apr 2020	Approval to be sought for COVID-19 Clinical Study in U.S.

20 Apr 2020	Receipt of cash payment for collateral shares

7 Apr 2020	Noxopharm trial data to be presented at ASCO 2020

2 Apr 2020	Updated Noxopharm Virtual Roadshow Corporate Presentation

1 Apr 2020	Noxopharm Investigating Potential COVID-19 Treatment

31 Mar 2020	Noxopharm Virtual Roadshow Corporate Presentation

26 Mar 2020	Initial Director's Interest Notice

26 Mar 2020	Appointment of New Board Member

17 Mar 2020	Veyonda Awarded First Allowed Patent Application

13 Mar 2020	Veyonda Clinical Program Update and Guidance

3 Mar 2020	LuPIN Prostate Cancer Trial Fully Recruited

27 Feb 2020	Noxopharm Corporate Presentation February 2020

25 Feb 2020	Half Year Accounts and Chairman Letter

21 Feb 2020	Section 708 Certificate

21 Feb 2020	Appendix 2A

21 Feb 2020	FDA grants IND approval to Veyonda

18 Feb 2020	Termination of Convertible Loan

18 Feb 2020	Section 708 Certificate

18 Feb 2020	Appendix 2A

18 Feb 2020	Noxopharm Alliance With GenesisCare

14 Feb 2020	Proposed issue of Securities - NOX

14 Feb 2020	$8.1M Financing & Re-Set of Capital Structure

14 Feb 2020	Pronounced survival benefit in LuPIN interim trial data

12 Feb 2020	Trading Halt

11 Feb 2020	LuPIN interim trial data to be presented at ASCO GU 2020

6 Feb 2020	Lapsing of Unlisted Options

31 Jan 2020	Noxopharm December 2019 Quarterly Activities Report & Appendix 4C

29 Jan 2020	Noxopharm Non-Deal Roadshow Presentation

20 Jan 2020	Appendix 3B

16 Jan 2020	Listing of Nyrada Inc. spin-off on ASX

16 Jan 2020	Becoming a substantial holder for NYR

15 Jan 2020	Noxopharm Corporate Presentation

27 Dec 2019	Ceasing to be a substantial holder

23 Dec 2019	Change of Director's Interest Notice - GK

23 Dec 2019	Section 708 Certificate

23 Dec 2019	Appendix 3B

20 Dec 2019	DARRT-1 Clinical Data Webinar

17 Dec 2019	Nyrada IPO Offer Fully Subscribed

13 Dec 2019	Unlisted Options Expiring 18 January 2020

9 Dec 2019	Lodgement of Nyrada Inc Supplementary Prospectus

4 Dec 2019	Nyrada Inc Initial Public Offering Opens

3 Dec 2019	Section 708 Certificate - Notes

3 Dec 2019	Section 708 Certificate

3 Dec 2019	Appendix 3B

3 Dec 2019	AU$2.4m Increase to Funding Agreement

3 Dec 2019	Section 708 Certificate

3 Dec 2019	Appendix 3B

2 Dec 2019	Positive DARRT-1 Data in Late-Stage Prostate Cancer

28 Nov 2019	Trading Halt

26 Nov 2019	Lodgement of Nyrada Inc Prospectus - Initial Public Offering

26 Nov 2019	Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive

20 Nov 2019	Constitution

20 Nov 2019	Results of Meeting

20 Nov 2019	Noxopharm 2019 AGM Corporate Presentations

12 Nov 2019	DARRT-1 Interim Data Presented To Conference

12 Nov 2019	LuPIN Data Being Presented To Conference

6 Nov 2019	Appointment of Chief Commercial Officer

30 Oct 2019	Noxopharm October 2019 Newsletter

30 Oct 2019	Appendix 4C - Quarterly Report for The Quarter Ending September 30, 2019

28 Oct 2019	Dr Graham Kelly to Assume CEO Role

25 Oct 2019	Appendix 3B

25 Oct 2019	Section 708 Certificate

22 Oct 2019	NOX and Nyrada TechKnow Invest Roadshow Presentations

21 Oct 2019	Durable Anti-Cancer Effect Confirmed in DARRT-1 Study

18 Oct 2019	Notice of 2019 Annual General Meeting & Proxy Form

18 Oct 2019	Potential Fundamental Change in Treatment of Brain Cancer

16 Oct 2019	New Executive Appointments and Board Change

16 Oct 2019	Final Director's Interest Notice

2 Oct 2019	Noxopharm 2019 Annual General Meeting Details

2 Oct 2019	FNN Interview: The LuPIN trial with Veyonda in prostate cancer

30 Sep 2019	Further Review Shows Major Clinical Benefits from Veyonda

26 Sep 2019	Corporate Governance Statement - Appendix 4G

26 Sep 2019	Corporate Governance Statement

26 Sep 2019	Section 708 Certificate

26 Sep 2019	Appendix 3B

26 Sep 2019	Noxopharm 2019 Annual Report

24 Sep 2019	Departure of Dr Van Wyk

17 Sep 2019	Veyonda and Radiotherapy Profiled at Key Oncology Meeting

16 Sep 2019	Results of Meeting

16 Sep 2019	NOX EGM Chairman's Address and Presentation

12 Sep 2019	CHANGE OF DIRECTOR'S INTEREST NOTICE - GK

10 Sep 2019	CHANGE OF DIRECTOR'S INTEREST NOTICE - GK

29 Aug 2019	Appendix 4E and Audited Financial Statements FY19

28 Aug 2019	Addendum to Notice of Extraordinary General Meeting

28 Aug 2019	More Evidence that Veyonda Enhances RT in Prostate Cancer

23 Aug 2019	NOX Receives FY19 Federal Government R&D Tax Rebate

23 Aug 2019	Appendix 3B

23 Aug 2019	Cleansing Statement

21 Aug 2019	Pre-Clinical Evidence Confirms Veyonda Abscopal Effect

15 Aug 2019	Lead Manager Appointed for Proposed Nyrada IPO

12 Aug 2019	Notice of Extraordinary General Meeting/Proxy Form

9 Aug 2019	Noxopharm Corporate Update Interview

7 Aug 2019	Noxopharm August 2019 Corporate Presentation

2 Aug 2019	NOX Releases Initial Newsletter for Nyrada Subsidiary

29 Jul 2019	Appendix 4C - Quarterly Report for the quarter ending June 30, 2019

25 Jul 2019	Appendix 3B

25 Jul 2019	Section 708 Certificate

23 Jul 2019	Appendix 3B

23 Jul 2019	Section 708 Certificate

19 Jul 2019	Initial Director's Interest Notice

19 Jul 2019	Final Director's Interest Notice

19 Jul 2019	NOX Announces AU$26 Million Funding Facility

17 Jul 2019	NOX Releases Latest Newsletter

16 Jul 2019	Board Changes Ahead of Corporate Growth

2 Jul 2019	LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019

26 Jun 2019	Conference Hears of Positive Interim Data from LuPIN Trial

7 Jun 2019	NOX Subsidiary, Nyrada Inc, Receives R&D Rebate

6 Jun 2019	Noxopharm Corporate Presentation June 2019

30 May 2019	DARRT-1 Study Fully Enrolled

23 May 2019	Promising Data Leads to Expansion of LuPIN Trial

20 May 2019	LuPIN Trial Demonstrates High Rates of Response

8 May 2019	Change of Director's Interest Notice - GK

8 May 2019	Appendix 3B

2 May 2019	DARRT Treatment Has Lasting Disease Control at Six Months

29 Apr 2019	Veyonda and Immuno-Oncology Effect Explained

26 Apr 2019	Appendix 4C - Quarterly

23 Apr 2019	Change in Noxopharm Limited Board Structure

16 Apr 2019	Idronoxil Confirmed as New Immuno-Oncology Drug

10 Apr 2019	Veyonda Chemotherapy Enhancement Program to be Expanded

8 Apr 2019	Securities to be released from Voluntary Escrow

5 Apr 2019	Updated Top 20 shareholder List

25 Mar 2019	Appendix 3B

25 Mar 2019	Section 708 Certificate

21 Mar 2019	Becoming a substantial holder

19 Mar 2019	KZA: Kazia sells stake in Noxopharm

6 Mar 2019	NOX provides update to Nyrada Note Holders

5 Mar 2019	New Corporate Presentation Released

21 Feb 2019	Noxopharm to expedite Veyonda Clinical Program

21 Feb 2019	Appendix 4D and Half Year Accounts

14 Feb 2019	Change of Director's Interest Notice - GK

6 Feb 2019	FNN interview with Nox Chief Medical Officer on Interim Data

6 Feb 2019	Veyonda and Radiotherapy Delivers Clinical Benefits

1 Feb 2019	Appendix 3B

29 Jan 2019	Appendix 4C - quarterly report for the quarter ended December 31, 2018

14 Jan 2019	Principal Investigator Discusses LuPIN-1 Study

21 Dec 2018	Change of Director's Interest Notice - GK

21 Dec 2018	Section 708 Certificate

21 Dec 2018	Appendix 3B

20 Dec 2018	NOX Receives $3.26M Federal Govt R&D Rebate

11 Dec 2018	DARRT-1 study advancing on basis of positive clinical data

29 Nov 2018	NOX announces Positive Data from CEP-1 Study of Veyonda

21 Nov 2018	Initial Director's Interest Notice

21 Nov 2018	Results of Meeting

21 Nov 2018	Appointment of Mr John Moore as Non-Executive Director

21 Nov 2018	NOX 2018 AGM Presentations

20 Nov 2018	NOX 2018 AGM Information

13 Nov 2018	NOX to Present Clinical Data at COSA Annual Meeting

8 Nov 2018	Corporate Presentation

26 Oct 2018	Appendix 4C - Quarterly report for the quarter ended September 30, 2018

22 Oct 2018	NOX makes key executive appointment

5 Oct 2018	Notice of Annual General Meeting & Proxy Form

4 Oct 2018	Noxopharm Releases Report on Key Progress of Subsidiary

2 Oct 2018	Section 708 Certificate

2 Oct 2018	Appendix 3B

28 Sep 2018	Change of Director's Interest Notice - PM

28 Sep 2018	Section 708 Certificate

28 Sep 2018	Appendix 3B

28 Sep 2018	Change of Registry Address: Automic P/L - Sydney Office

27 Sep 2018	Annual Report to shareholders

27 Sep 2018	Corporate Governance Statement - Appendix 4G

27 Sep 2018	Corporate Governance Statement - 2018

24 Sep 2018	NOX Subsidiary Announces Important Drug Discovery

5 Sep 2018	NOX to support expanded LuPIN study

30 Aug 2018	Appendix 4E and Audited Financial Statements

27 Aug 2018	Nyrada-Key progress with cholesterol-lowering drug candidate

20 Aug 2018	VEYONDA - Registered Trade Mark for NOX66

9 Aug 2018	Change of Director's Interest Notice - GK

9 Aug 2018	Change of Director's Interest Notice - PM

9 Aug 2018	Change of Director's Interest Notice - ID

9 Aug 2018	Appendix 3B

8 Aug 2018	Interim NOX66 Radiotherapy Clinical Data

30 Jul 2018	Appendix 4C- Quarterly report for the quarter ended June 30, 2018

10 Jul 2018	Securities to be released from Escrow

9 Jul 2018	Release of DARRT-1 Preliminary Safety Data

5 Jul 2018	Pre-Clinical data confirms Radio-Enhancing potential

7 Jun 2018	Noxopharm Corporate Presentation for Public Briefing

5 Jun 2018	End-of-Study Clinical Data shows benefit of NOX66

31 May 2018	Noxopharm 2018 Mid-Year Investor Briefings

28 May 2018	Section 708 Certificate

28 May 2018	Appendix 3B

22 May 2018	NOX to present at American Society of Clinical Oncology

21 May 2018	Change in substantial holding

21 May 2018	Securities to be released from Voluntary Escrow

21 May 2018	Section 708 Certificate

21 May 2018	Appendix 3B

18 May 2018	Noxopharm 2018 Mid-Year Investor Briefings

15 May 2018	Results of Meeting

7 May 2018	NOX CEO interview updates the company's current R&D program

3 May 2018	NOX CEO interview on near complete NOX66 chemotherapy trial

27 Apr 2018	NOX CEO interview on Radiotherapy Clinical Programs

27 Apr 2018	Appendix 4C - quarterly

17 Apr 2018	St Vincent's Hospital study passes first milestone

9 Apr 2018	Notice of Extraordinary General Meeting / Proxy Form

6 Apr 2018	Change in substantial holding

6 Apr 2018	Change in substantial holding

5 Apr 2018	DARRT-1 Clinical Study commences

5 Apr 2018	NOX Mid-Year Briefings

29 Mar 2018	Section 708 Certificate

29 Mar 2018	Appendix 3B

23 Mar 2018	NOX raises $10.8 M to advance clinical program

21 Mar 2018	Trading Halt

21 Mar 2018	Evidence of Abscopal Responses in Patients

12 Mar 2018	Corporate Presentation - Post Interim Clinical Data Release

9 Mar 2018	FNN Interview with Noxopharm CEO

6 Mar 2018	NOX Reports NOX66 Clinical Data

5 Mar 2018	Trading Halt

23 Feb 2018	Update accompanying Half Year Report

23 Feb 2018	Appendix 4D and Half Year Accounts

16 Feb 2018	NOX closes $4m capital raising for US subsidiary Nyrada Inc

31 Jan 2018	Appendix 4C - quarterly

25 Jan 2018	Section 708 Certificate

25 Jan 2018	Appendix 3B

18 Jan 2018	Section 708 Certificate

18 Jan 2018	Appendix 3B

17 Jan 2018	NOX receives FY17 R&D Tax Rebate

27 Dec 2017	Kazia Therapeutics Ltd and Noxopharm Ltd

21 Dec 2017	EOY Guidance on 2018 NOX66 Clinical Development Strategy

19 Dec 2017	Section 708 Certificate

19 Dec 2017	Appendix 3B

14 Dec 2017	Response to ASX Price Query

12 Dec 2017	Appendix 3B

11 Dec 2017	Change of Registered Office

7 Dec 2017	Section 708 Certificate

7 Dec 2017	Appendix 3B

6 Dec 2017	NOX Open Briefing Corporate Presentation

4 Dec 2017	Compassionate use of NOX66 in Patients

1 Dec 2017	Nyrada Inc Opens Capital Raise - Memorandum Released

29 Nov 2017	Change of Director's Interest Notice - PM

29 Nov 2017	Change of Director's Interest Notice - ID

29 Nov 2017	Appendix 3B

29 Nov 2017	Webcast of NOX 2017 AGM

29 Nov 2017	NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model

28 Nov 2017	Invitation to Open Briefing

27 Nov 2017	Results of Meeting

27 Nov 2017	AGM Presentations

23 Nov 2017	Clarification of Incorrect Information

23 Nov 2017	Trading Halt

21 Nov 2017	NOX 2017 AGM Webcast

21 Nov 2017	Completion of Transfer of Shares to Nyrada Inc

20 Nov 2017	Promising Interim Clinical Data for NOX66

17 Nov 2017	Trading Halt

16 Nov 2017	1st Patient treated in Lupin Study at St Vincent's Hospital

15 Nov 2017	Section 708 Certificate

15 Nov 2017	Appendix 3B

13 Nov 2017	NOX making three presentations at COSA

7 Nov 2017	Section 708 Certificate

7 Nov 2017	Appendix 3B

6 Nov 2017	Results of Meeting

6 Nov 2017	EGM Presentations

3 Nov 2017	UNSW collaboration confirms drug designed for stroke victims

30 Oct 2017	Appendix 4C – Quarterly report for the quarter ended September 30, 2017

26 Oct 2017	Notice of Annual General Meeting/Proxy Form

26 Oct 2017	Noxopharm 2017 Annual Report

23 Oct 2017	Update - General Meeting Agenda

19 Oct 2017	October 2017 Open Briefing Corporate Presentation

13 Oct 2017	Invitation to Open Briefing

4 Oct 2017	Establishment of Nyrada Inc. - Extraordinary General Meeting

27 Sep 2017	Australian NOX66 - Radiotherapy Study Opens

25 Sep 2017	Establishment of Nyrada Inc.

12 Sep 2017	Positive Clinical Outcomes for NOX66 at ESMO Conference

7 Sep 2017	Change in substantial holding

6 Sep 2017	Change in substantial holding

4 Sep 2017	Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice

4 Sep 2017	NOX CEO Interview explains recent Brain Cancer Announcement

31 Aug 2017	Appendix 4E and Audited Financial Statements

31 Aug 2017	Corporate Governance Statement - Appendix 4G

31 Aug 2017	Corporate Governance Statement

29 Aug 2017	Important Brain Cancer Findings for NOX66 Program

24 Aug 2017	Reinstatement to Official Quotation

24 Aug 2017	Noxopharm raises $5.5 million to advance clinical program

23 Aug 2017	Suspension from Official Quotation

21 Aug 2017	Trading Halt Request

21 Aug 2017	Trading Halt

8 Aug 2017	NOX Corporate Presentation ahead of Conference

31 Jul 2017	Appendix 4C - quarterly

27 Jul 2017	NOX Research Report prepared by APP Securities

25 Jul 2017	CEO Interview with FNN - Singapore and HK Roadshow

25 Jul 2017	New Corporate Presentation

6 Jul 2017	Noxopharm provides update on NOX66 Clinical Trial Program

19 Jun 2017	Idronoxil data provides hope to treat secondary brain cancer

5 Jun 2017	NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment

30 May 2017	New Corporate Presentation

29 May 2017	St Vincents Cancer Study to Commence-NOX66 and Radiotherapy

24 May 2017	NOX makes strategic commitment to treatment of rare cancers

18 May 2017	Noxopharm Mid Year Investor Briefings

2 May 2017	Market Guidance for Next Six Months

27 Apr 2017	Appendix 4C - quarterly

10 Apr 2017	FNN Interview with NOX CEO Explaining Idronoxil-C Discovery

10 Apr 2017	NOX Files Patent Application on 'Smart' Idronoxil

3 Apr 2017	Appendix 3B

27 Mar 2017	NOX and Monash Uni Collaboration Receives Federal Grant

16 Mar 2017	Noxopharm and UNSW combine on stroke project

10 Mar 2017	Gold Coast Qld Mid-Year Briefing Details

7 Mar 2017	Notification of Release of Restricted Securities Escrow

3 Mar 2017	NOX researching rare Abscopal Response

24 Feb 2017	Appendix 4D and Half Year Accounts

24 Feb 2017	NOX Presentation and Interview ASX The CEO Sessions

21 Feb 2017	ASX CEO Presentation Feb 2017 slides

15 Feb 2017	Upcoming Events and Presentations

3 Feb 2017	Change of Principal Place of Business

1 Feb 2017	Brain Cancer Study Commences

31 Jan 2017	First NOX66 Clinical Trial to Commence

30 Jan 2017	Appendix 4C – Quarterly report for the quarter ended 31 December 2016

16 Jan 2017	Appointment of New Company Secretary

9 Jan 2017	Appendix 3B

20 Dec 2016	Change in substantial holding

20 Dec 2016	Change of Director's Interest Notice - ID

20 Dec 2016	Change of Director's Interest Notice - GK

20 Dec 2016	Market Capitalisation - further update

20 Dec 2016	Appendix 3B

19 Dec 2016	Market Capitalisation Update

23 Nov 2016	Results of Meeting

23 Nov 2016	Breakthrough in Delivering Idronoxil into Brain

22 Nov 2016	Corporate Presentation Updated

22 Nov 2016	Corporate Presentation Providing Clinical Program Guidance

17 Nov 2016	Medical Advisors Appointed for Extensive Clinical Program

14 Nov 2016	Change in substantial holding DH

31 Oct 2016	Appendix 4C - quarterly

24 Oct 2016	Noxopharm 2016 AGM Sydney Briefing

21 Oct 2016	Noxopharm 2016 Annual Report

20 Oct 2016	Corporate Presentation

3 Oct 2016	Appendix 4G

30 Sep 2016	Amendment to Preliminary Final Report

12 Sep 2016	Corporate Presentation for Roadshow

31 Aug 2016	Preliminary Final Report

25 Aug 2016	Change in substantial holding

22 Aug 2016	Change in substantial holding DH

22 Aug 2016	Noxopharm to Initiate Radiotherapy Clinical Studies

19 Aug 2016	Change of Director's Interest Notice - GK

10 Aug 2016	Becoming a substantial holder

10 Aug 2016	Becoming a substantial holder

10 Aug 2016	Becoming a substantial holder

10 Aug 2016	Initial Director's Interest Notice - PM

10 Aug 2016	Initial Director's Interest Notice - ID

10 Aug 2016	Initial Director's Interest Notice - GK

9 Aug 2016	Noxopharm Limited commences trading on ASX

8 Aug 2016	Performance Share Terms

8 Aug 2016	Option Terms

8 Aug 2016	Restricted Securities and Capital Structure

8 Aug 2016	Securities Trading Policy

8 Aug 2016	Financial Accounts

8 Aug 2016	Constitution

8 Aug 2016	ASX Market Release - Admission to Official List

8 Aug 2016	Appendix 1A & Information Form and Checklist

8 Aug 2016	Top 20 Holders

8 Aug 2016	Distribution Schedule

8 Aug 2016	Company's Admission Disclosures

8 Aug 2016	ASX Market Release - Pre-Quotation Disclosure

8 Aug 2016	Prospectus

8 Aug 2016	ASX Notice - Admission and Commencement of Quotation

Copyright © Noxopharm